Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents

Published:2022-01-28 Issue:3 Volume:12 Page:631-642
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Sidbury Robert,Alpizar Sady,Laquer Vivian,Dhawan Sunil,Abramovits William,Loprete Luca,Krishnaswamy Jayendar Kumar,Ahmad Faiz,Jabbar-Lopez Zarif,Piketty Christophe^ORCID

Funder

Galderma

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-021-00678-7.pdf

Reference21 articles.

1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109–22.

2. Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126:417-28 e2.

3. Eichenfield LF, Totri C. Optimizing outcomes for paediatric atopic dermatitis. Br J Dermatol. 2014;170(Suppl 1):31–7.

4. Legat FJ. Itch in atopic dermatitis—what is new? Front Med (Lausanne). 2021;8:644760.

5. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284–93.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond;Expert Opinion on Biological Therapy;2024-06-02

2. A critical evaluation of nemolizumab for prurigo nodularis;Expert Review of Clinical Immunology;2024-01-19

3. Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: A systematic review in pediatric patients;Pediatric Dermatology;2023-11-28

4. The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents;Immunotherapy;2023-11

5. Biologics and oral small‐molecule inhibitors for treatment of pediatric atopic dermatitis: Opportunities and challenges;Pediatric Investigation;2023-09